Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis
Background/Aims Previous studies have revealed that glucagon-like peptide-1 receptor agonist (GLP-1RA) and thiazolidinedione (TZD) can improve nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). However, comprehensive research comparing the effects of GLP-1RA and TZD is...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Association for the Study of the Liver
2023-07-01
|
| Series: | Clinical and Molecular Hepatology |
| Subjects: | |
| Online Access: | http://e-cmh.org/upload/pdf/cmh-2022-0330.pdf |
| _version_ | 1797777419573133312 |
|---|---|
| author | Min Jeong Park Hayeon Kim Myeong Gyu Kim Kyungim Kim |
| author_facet | Min Jeong Park Hayeon Kim Myeong Gyu Kim Kyungim Kim |
| author_sort | Min Jeong Park |
| collection | DOAJ |
| description | Background/Aims Previous studies have revealed that glucagon-like peptide-1 receptor agonist (GLP-1RA) and thiazolidinedione (TZD) can improve nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). However, comprehensive research comparing the effects of GLP-1RA and TZD is limited. Thus, this study aimed to compare the effects of GLP-1RA and TZD on NAFLD or NASH through a network meta-analysis. Methods The PubMed, Embase, Web of Science, and Scopus databases were searched for randomized controlled trials (RCTs) that explored the efficacy of GLP-1RAs or TZDs in adult patients with NAFLD or NASH. The outcomes were liver biopsy-based (NAFLD activity score [NAS], fibrosis stage, and NASH resolution), noninvasive technique-based (liver fat content on proton magnetic resonance spectroscopy [1H-MRS] and controlled attenuation parameter [CAP]), biological, and anthropometric indicators. A random effects model was used to calculate the mean difference (MD) and relative risk with 95% confidence interval (CI). Results Twenty-five RCTs with 2,237 overweight or obese patients were included. GLP-1RA was significantly superior in reducing liver fat content evaluated using 1H-MRS (MD –2.42, 95% CI –3.84 to –1.00), body mass index (MD –1.60, 95% CI –2.41 to –0.80), and waist circumference (MD –4.89, 95% CI –8.17 to –1.61) than TZD. In liver biopsy-based evaluation and liver fat content assessment using CAP, GLP-1RA tended to surpass TZD, albeit not significantly. Sensitivity analysis showed consistent results with the main results. Conclusions Compared with TZD, GLP-1RA had better effects on liver fat content, body mass index, and waist circumference in overweight or obese patients with NAFLD or NASH. |
| first_indexed | 2024-03-12T23:03:46Z |
| format | Article |
| id | doaj.art-79adbb31bcd94c0a9923bf0b147eb19a |
| institution | Directory Open Access Journal |
| issn | 2287-2728 2287-285X |
| language | English |
| last_indexed | 2024-03-12T23:03:46Z |
| publishDate | 2023-07-01 |
| publisher | Korean Association for the Study of the Liver |
| record_format | Article |
| series | Clinical and Molecular Hepatology |
| spelling | doaj.art-79adbb31bcd94c0a9923bf0b147eb19a2023-07-19T06:44:39ZengKorean Association for the Study of the LiverClinical and Molecular Hepatology2287-27282287-285X2023-07-0129369370410.3350/cmh.2022.03301790Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysisMin Jeong Park0Hayeon Kim1Myeong Gyu Kim2Kyungim Kim3 Division of Endocrinology & Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea College of Pharmacy, Korea University, Sejong, Korea College of Pharmacy, Ewha Womans University, Seoul, Korea College of Pharmacy, Korea University, Sejong, KoreaBackground/Aims Previous studies have revealed that glucagon-like peptide-1 receptor agonist (GLP-1RA) and thiazolidinedione (TZD) can improve nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). However, comprehensive research comparing the effects of GLP-1RA and TZD is limited. Thus, this study aimed to compare the effects of GLP-1RA and TZD on NAFLD or NASH through a network meta-analysis. Methods The PubMed, Embase, Web of Science, and Scopus databases were searched for randomized controlled trials (RCTs) that explored the efficacy of GLP-1RAs or TZDs in adult patients with NAFLD or NASH. The outcomes were liver biopsy-based (NAFLD activity score [NAS], fibrosis stage, and NASH resolution), noninvasive technique-based (liver fat content on proton magnetic resonance spectroscopy [1H-MRS] and controlled attenuation parameter [CAP]), biological, and anthropometric indicators. A random effects model was used to calculate the mean difference (MD) and relative risk with 95% confidence interval (CI). Results Twenty-five RCTs with 2,237 overweight or obese patients were included. GLP-1RA was significantly superior in reducing liver fat content evaluated using 1H-MRS (MD –2.42, 95% CI –3.84 to –1.00), body mass index (MD –1.60, 95% CI –2.41 to –0.80), and waist circumference (MD –4.89, 95% CI –8.17 to –1.61) than TZD. In liver biopsy-based evaluation and liver fat content assessment using CAP, GLP-1RA tended to surpass TZD, albeit not significantly. Sensitivity analysis showed consistent results with the main results. Conclusions Compared with TZD, GLP-1RA had better effects on liver fat content, body mass index, and waist circumference in overweight or obese patients with NAFLD or NASH.http://e-cmh.org/upload/pdf/cmh-2022-0330.pdfglucagon-like peptide-1 receptor agonistthiazolidinedionesnonalcoholic steatohepatitisnonalcoholic fatty liver diseasenetwork meta-analysis |
| spellingShingle | Min Jeong Park Hayeon Kim Myeong Gyu Kim Kyungim Kim Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis Clinical and Molecular Hepatology glucagon-like peptide-1 receptor agonist thiazolidinediones nonalcoholic steatohepatitis nonalcoholic fatty liver disease network meta-analysis |
| title | Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis |
| title_full | Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis |
| title_fullStr | Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis |
| title_full_unstemmed | Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis |
| title_short | Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis |
| title_sort | comparison of glucagon like peptide 1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease a network meta analysis |
| topic | glucagon-like peptide-1 receptor agonist thiazolidinediones nonalcoholic steatohepatitis nonalcoholic fatty liver disease network meta-analysis |
| url | http://e-cmh.org/upload/pdf/cmh-2022-0330.pdf |
| work_keys_str_mv | AT minjeongpark comparisonofglucagonlikepeptide1receptoragonistsandthiazolidinedionesontreatingnonalcoholicfattyliverdiseaseanetworkmetaanalysis AT hayeonkim comparisonofglucagonlikepeptide1receptoragonistsandthiazolidinedionesontreatingnonalcoholicfattyliverdiseaseanetworkmetaanalysis AT myeonggyukim comparisonofglucagonlikepeptide1receptoragonistsandthiazolidinedionesontreatingnonalcoholicfattyliverdiseaseanetworkmetaanalysis AT kyungimkim comparisonofglucagonlikepeptide1receptoragonistsandthiazolidinedionesontreatingnonalcoholicfattyliverdiseaseanetworkmetaanalysis |